Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Drugs
Published in: Drugs 8/2014

01-06-2014 | R&D Insight Report

Tofogliflozin: First Global Approval

Authors: Raewyn M. Poole, Jennifer E. Prossler

Published in: Drugs | Issue 8/2014

Login to get access

Abstract

Tofogliflozin (Apleway®, Deberza® [Japan]), an orally active small molecule sodium-glucose co-transporter type 2 (SGLT2) inhibitor, has been developed by Chugai Pharmaceutical for the treatment of type 2 diabetes mellitus (T2DM), and a marketing authorization application was filed in Japan in 2013 by licensees Sanofi K.K. and Kowa. Tofogliflozin has received its first global approval for this indication in Japan as either monotherapy or in combination with other antihyperglcaemic agents. This article summarizes the milestones in the development of tofogliflozin leading to this first approval for the treatment of T2DM.
Literature
1.
Chao EC. SGLT-2 inhibitors: a new mechanism for glycemic control. Clin Diabetes. 2014;32(1):4–11.CrossRef
2.
Liu J, Lee T, DeFronzo RA. Why do SGLT2 inhibitors inhibit only 30-50% of renal glucose reabsorption in humans? Diabetes. 2012;61(9):2199–204.PubMedCrossRef
3.
Misra M. SGLT2 inhibitors: a promising new therapeutic option for treatment of type 2 diabetes mellitus. J Pharm Pharmacol. 2013;65(3):317–27.PubMedCrossRef
4.
Rosenwasser RF, Sultan S, Sutton D, et al. SGLT-2 inhibitors and their potential in the treatment of diabetes. Diabetes Metab Syndr Obesity Targets Ther. 2013;6:453–67.
5.
Raskin P. Sodium-glucose cotransporter inhibition: Therapeutic potential for the treatment of type 2 diabetes mellitus. Diabetes Metab Res Rev. 2013;29(5):347–56.PubMedCrossRef
6.
Tahrani AA, Barnett AH, Bailey CJ. SGLT inhibitors in management of diabetes. Lancet Diabetes Endocrinol. 2013;1(2):140–51.PubMedCrossRef
7.
Washburn WN, Poucher SM. Differentiating sodium-glucose co-transporter-2 inhibitors in development for the treatment of type 2 diabetes mellitus. Expert Opin Investig Drugs. 2013;22(4):463–86.PubMedCrossRef
8.
Sanofi. Media release 24 March 2014 [Japanese]. 2014.
9.
Sanofi. Tofogliflozin prescribing information [Japanese]. 2014.
10.
Kowa. Tofogliflozin prescribing information [Japanese]. 2014.
11.
Chugai Pharmaceutical Co. License agreement of SGLT2 inhibitor “CSG452” in Japan. Media Release. 2012.
12.
Chugai Pharmaceutical Co. Roche returns development and marketing rights of SGLT2 Inhibitor “CSG452” to Chugai. Media Release. 2011.
13.
Suzuki M, Honda K, Fukazawa M, et al. Tofogliflozin, a potent and highly specific sodium/glucose cotransporter 2 inhibitor, improves glycemic control in diabetic rats and mice. J Pharmacol Exp Ther. 2012;341(3):692–701.PubMedCrossRef
14.
Yamaguchi K, Kato M, Suzuki M, et al. In vitro-in vivo correlation of the inhibition potency of sodium-glucose cotransporter inhibitors in rat: a pharmacokinetic and pharmacodynamic modeling approach. J Pharmacol Exp Ther. 2013;345(1):52–61.PubMedCrossRef
15.
Obata A, Kubota N, Kubota T, et al. Tofogliflozin improves insulin resistance as well as glucose tolerance by ameliorating fatty liver and obesity. Diabetes. 2013;62:A285–6.
16.
Fukazawa M, Nagata T, Murao N, et al. Compensatory effect of endogenous glucose production (EGP) after acute urinary glucose excretion (UGE) from selective SGLT2 inhibition with tofogliflozin (TOFO) or SGLT1/2 inhibition with phlorizin (PHZ) in normal and diabetic rats. Diabetes. 2012;61:A286.
17.
Nagata T, Fukazawa M, Honda K, et al. Selective SGLT2 inhibition by tofogliflozin reduces renal glucose reabsorption under hyperglycemic but not under hypo- or euglycemic conditions in rats. Am J Physiol Endocrinol Metab. 2013;304(4):E414–23.PubMedCrossRef
18.
Nagata T, Fukuzawa T, Takeda M, et al. Tofogliflozin, a novel sodium-glucose co-transporter 2 inhibitor, improves renal and pancreatic function in db/db mice. Br J Pharmacol. 2013;170(3):519–31.PubMedCrossRef
19.
Fukuzawa T, Nagata T, Takeda M, et al. Tofogliflozin, a novel sodium-glucose co-transporter 2 inhibitor, improves pancreatic and renal functions in animal models of type 2 diabetes. Diabetes. 2011;60:A312.
20.
Kadowaki T, Ikeda S, Takano Y, et al. Tofogliflozin, a novel and selective SGLT2 inhibitor improves glycemic control and lowers body weight in patients with type 2 diabetes mellitus inadequately controlled on stable metformin or diet and exercise alone. Diabetes. 2012;61:A22.CrossRef
21.
Zell M, Husser C, Kuhlmann O, et al. Metabolism and mass balance of SGLT2 inhibitor tofogliflozin following oral administration to humans. Xenobiotica. 2014;44(4):369–78.PubMedCrossRef
22.
Schwab D, Portron A, Backholer Z, et al. A novel double-tracer technique to characterize absorption, distribution, metabolism and excretion (ADME) of [14C]tofogliflozin after oral administration and concomitant intravenous microdose administration of [13C]tofogliflozin in humans. Clin Pharmacokinet. 2013;52(6):463–73.PubMedCrossRef
23.
Schwab D, Portron A, Fukushima Y, et al. Tofogliflozin a selective SGLT2 inhibitor exhibits highly favourable drug properties for use in patients with renal impairment and for combination with other medicines. Diabetologia. 2012;55:S316.
24.
Tanizawa Y, Kaku K, Araki E, et al. Long-term safety and efficacy of tofogliflozin, a selective inhibitor of sodium-glucose cotransporter 2, as monotherapy or in combination with other oral antidiabetic agents in Japanese patients with type 2 diabetes mellitus: multicenter, open-label, randomized controlled trials. Expert Opin Pharmacother. 2014;15(6):749–66.PubMedCrossRef
25.
Matsuda M, DeFronzo R. Insulin sensitivity indices obtained from oral glucose tolerance testing: comparison with the euglycemic insulin clamp. Diabetes Care. 1999;22(9):1462–90.PubMedCrossRef
26.
Araki E, Kaku K, Watada H, et al. Verification of the efficacy and safety of tofogliflozin, a novel SGLT2 inhibitor, in Japanese patients with type 2 diabetes mellitus: results from a phase 2/3 clinical study. In: 49th Annual Meeting of the European Association for the Study of Diabetes. 2013, abstr. 929.
27.
Ikeda S, Takano Y, Cynshi O, et al. A novel and selective SGLT2 inhibitor, tofogliflozin improves glycaemic control and lowers body weight in patients with type 2 diabetes mellitus. Diabetologia. 2012;55:S316.
Metadata
Title
Tofogliflozin: First Global Approval
Authors
Raewyn M. Poole
Jennifer E. Prossler
Publication date
01-06-2014
Publisher
Springer International Publishing
Published in
Drugs / Issue 8/2014
Print ISSN: 0012-6667
Electronic ISSN: 1179-1950
DOI
https://doi.org/10.1007/s40265-014-0229-1

Other articles of this Issue 8/2014

Drugs 8/2014 Go to the issue

Review Article

Pharmacokinetics and Pharmacodynamics of Antifungals in Children: Clinical Implications

Leading Article

Lithium in the Treatment of Major Depressive Disorder

R&D Insight Report

Luseogliflozin: First Global Approval

Review Article

First-Line and Maintenance Therapy for Ovarian Cancer: Current Status and Future Directions

Review Article

The Evolution of Insulin Glargine and its Continuing Contribution to Diabetes Care

R&D Insight Report

Albiglutide: First Global Approval